Burimi RSS i ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted

Pyetje

Cila është URL-ja e burimit RSS për ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted?

Adresa e burimit është https://clinicaltrials.gov/api/rss?term=%28%22generalized+myasthenia+gravis%22+OR+%22myasthenia+gravis%22%29+AND+%28eculizumab+OR+ravulizumab+OR+gefurulimab+OR+inebilizumab+OR+nipocalimab+OR+zilucoplan+OR+rozanolixizumab+OR+efgartigimod+OR+remibrutinib%29&dateField=LastUpdatePostDate. Ngjiteni në cilindo lexues RSS ose klikoni Ndiq tani për ta lexuar në Feeder.

Sa shpesh publikon ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted?

ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted publikon rreth 5 herë në javë. Postimi i fundit ishte para 5 ditë.

A funksionon burimi RSS i ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted?

Po. Feeder e kontrolloi para 4 minuta dhe burimi u përgjigj normalisht.

Si ta ndjek ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted në Feeder?

Klikoni Ndiq tani dhe regjistrohuni nëse nuk keni ende llogari. Plani falas i Feeder mbulon deri në 200 burime, në ueb, iPhone dhe Android. Nuk kërkohet kartë krediti.